BioCentury | Jul 25, 2011
Clinical News

IHD-Amy test diagnostic data

...32 healthy volunteers and 18 patients with multiple sclerosis (MS) showed that Innovative Health Diagnostic's IHD-Amy...
...presented at the International Conference on Alzheimer's Disease in Paris. Innovative Health Diagnostics , Strasbourg, France Product: IHD-Amy...
BioCentury | Oct 8, 2007
Regulation

Significant isn't meaningful

...chest pain. Frovatriptan is contraindicated in patients with ischemic heart disease (IHD), symptoms consistent with IHD...
BioCentury | Nov 13, 2006
Product Development

Under pressure

...showed an association between blood pressure increases and age-specific mortality from stroke, ischemic heart disease (IHD...
...mm Hg "would involve about 10% lower stroke mortality and about 7% lower mortality from IHD...
BioCentury | Nov 4, 2002
Finance

Restructuring watch

...to $7M. Focusing on Del-1 gene medicine for peripheral arterial disease(PAD) and ischemic heart disease (IHD...
BioCentury | Oct 21, 2002
Company News

Valentis cancer, gene/cell therapy news

...lead products, Del-1 gene medicine to treat peripheral arterial disease (PAD) and ischemic heart disease (IHD...
Items per page:
1 - 5 of 5
BioCentury | Jul 25, 2011
Clinical News

IHD-Amy test diagnostic data

...32 healthy volunteers and 18 patients with multiple sclerosis (MS) showed that Innovative Health Diagnostic's IHD-Amy...
...presented at the International Conference on Alzheimer's Disease in Paris. Innovative Health Diagnostics , Strasbourg, France Product: IHD-Amy...
BioCentury | Oct 8, 2007
Regulation

Significant isn't meaningful

...chest pain. Frovatriptan is contraindicated in patients with ischemic heart disease (IHD), symptoms consistent with IHD...
BioCentury | Nov 13, 2006
Product Development

Under pressure

...showed an association between blood pressure increases and age-specific mortality from stroke, ischemic heart disease (IHD...
...mm Hg "would involve about 10% lower stroke mortality and about 7% lower mortality from IHD...
BioCentury | Nov 4, 2002
Finance

Restructuring watch

...to $7M. Focusing on Del-1 gene medicine for peripheral arterial disease(PAD) and ischemic heart disease (IHD...
BioCentury | Oct 21, 2002
Company News

Valentis cancer, gene/cell therapy news

...lead products, Del-1 gene medicine to treat peripheral arterial disease (PAD) and ischemic heart disease (IHD...
Items per page:
1 - 5 of 5